572 related articles for article (PubMed ID: 21862454)
1. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
2. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
3. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
4. Free water transport in children on peritoneal dialysis is higher with more biocompatible dialysis solutions, higher with older age and declines with time.
Raaijmakers R; Coester A; Smit W; Krediet RT; Schröder CH
Nephrol Dial Transplant; 2012 Mar; 27(3):1183-90. PubMed ID: 21771747
[TBL] [Abstract][Full Text] [Related]
5. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
6. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
[TBL] [Abstract][Full Text] [Related]
7. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
8. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.
Lee HY; Choi HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Kim MJ; Shin SK
Nephrol Dial Transplant; 2006 Oct; 21(10):2893-9. PubMed ID: 16957012
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.
Rodrigues AS; Almeida M; Fonseca I; Martins M; Carvalho MJ; Silva F; Correia C; Santos MJ; Cabrita A
Nephrol Dial Transplant; 2006 Mar; 21(3):763-9. PubMed ID: 16332703
[TBL] [Abstract][Full Text] [Related]
10. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
[TBL] [Abstract][Full Text] [Related]
11. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
12. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study.
Cho JH; Hur IK; Kim CD; Park SH; Ryu HM; Yook JM; Choi JY; Choi HJ; Choi HJ; Park JW; Do JY; Kim YL
Nephrol Dial Transplant; 2010 Jun; 25(6):1964-73. PubMed ID: 20100731
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
15. Biocompatible dialysis fluids for peritoneal dialysis.
Htay H; Johnson DW; Wiggins KJ; Badve SV; Craig JC; Strippoli GF; Cho Y
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007554. PubMed ID: 30362116
[TBL] [Abstract][Full Text] [Related]
16. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
[TBL] [Abstract][Full Text] [Related]
17. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
18. Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients.
Choi HY; Lee JE; Han SH; Yoo TH; Kim BS; Park HC; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2010 Apr; 25(4):1266-71. PubMed ID: 19926717
[TBL] [Abstract][Full Text] [Related]
19. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
Wang J; Zhu N; Yuan W
Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
[TBL] [Abstract][Full Text] [Related]
20. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial.
Jiang N; Qian J; Sun W; Lin A; Cao L; Wang Q; Ni Z; Wan Y; Linholm B; Axelsson J; Yao Q
Nephrol Dial Transplant; 2009 Aug; 24(8):2551-8. PubMed ID: 19258386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
